-
Doubling down in diabetes Merck's diabetes deals Merck & Co. Inc. has signed at least 12 diabetes-related deals since the pharma and Bristol-Myers Squibb Co. terminated a co-development deal for BMS's Pargluva …
Published on 5/6/2013
-
As sales flatten for Merck's sitagliptin franchise and a new class of oral diabetes drugs comes to market, the pharma has tapped Pfizer and Abide to shore up its position.
Published on 5/6/2013
-
Celgene has identified protein homeostasis as the next area of breakthrough science where it wants to place a large bet, and has put its chips on Forma's discovery platform.
Published on 5/6/2013
-
By creating a global specialty medicines unit, Teva aims to accelerate worldwide launches of branded innovator drugs for itself, as well as for partners who don't command Teva's strong commercial footprint.
Published on 4/29/2013
-
Two years into the job at Sanofi, Elias Zerhouni has shaken up the company's R&D structure, dumped programs and reoriented toward disease biology. But he says the real evidence of change won't come until 2016.
Published on 4/29/2013
-
Zerhouni's progress report Sanofi then & now Since he began his strategic review in early 2009, Elias Zerhouni, head of global R&D at Sanofi (Euronext:SAN; NYSE:SNY), has focused on advancing programs with novel …
Published on 4/29/2013
-
Zerhouni's progress report Sanofi's discontinued programs Sanofi (Euronext:SAN; NYSE:SNY) is no longer purusing 19 of the 27 NMEs that were in Phase II or Phase III/registration at the start of 2009. Some of the …
Published on 4/29/2013
-
With the most stocked clinical pipeline among its RNAi peers, Alnylam has made the leap from platform to products, providing a case study for the use of IP for company building and sustainable finance.
Published on 4/15/2013
-
IP armamentarium Alnylam chronicles With so many of its early years devoted to figuring out RNAi delivery, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had to depend on its investors, who weren't always patient, …
Published on 4/15/2013
-
IP armamentarium Dealing in RNAi As it transitions from a pure platform play to a product company, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) continues to do deals for its RNAi technology as well as partnerships for…
Published on 4/15/2013
-
AstraZeneca's reset AstraZeneca's pipeline fast track AstraZeneca plc (LSE:AZN; NYSE:AZN) has prioritized six therapeutics to be advanced into Phase III or pivotal testing as fast as possible. Of the six, four are …
Published on 4/8/2013
-
Following a spending spree for late-stage assets in 2012, AZ believes its Phase II/III pipeline now can restore long-term growth on the back of a revamped commercial strategy in emerging markets and Japan.
Published on 4/8/2013
-
With two deals in as many weeks, Shire has set its sights on ophthalmics as its next specialty play. Similar deals could be in the offing, according to incoming CEO Flemming Ornskov.
Published on 4/1/2013
-
The big upfront in Moderna's partnership with AstraZeneca will allow the biotech to scale up its therapeutic mRNA platform and develop its own clinical programs.
Published on 3/25/2013
-
NPS has regained two drugs from Takeda at a discount; now the biotech will be looking to establish a global footprint on the backs of Gattex and Natpara.
Published on 3/25/2013
-
Japan's biggest biotech Kyowa's pipeline Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) and its partners have at least 25 compounds in clinical development, excluding line extensions and drugs already marketed by the …
Published on 3/18/2013
-
Japan's biggest biotech Kyowa's sales by segment Over the last four years, Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) has simplified its business to focus on two main revenue streams -- pharmaceuticals and biochemicals…
Published on 3/18/2013
-
Japan's biggest biotech Kyowa's deal flow Since 2010, Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) has done at least 13 pipeline building deals. Nine were discovery or preclinical stage. Most recent deals at top. (A) JV …
Published on 3/18/2013
-
Japan's biggest biotech Kyowa's pipeline Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) and its partners have at least 25 compounds in clinical development, excluding line extensions and drugs already marketed by the …
Published on 3/18/2013
-
Japan's biggest biotech Kyowa's top five drugs The top five drugs from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) accounted for ¥135.9 billion ($1.7 billion) in sales, or about 54% of total net sales from the …
Published on 3/18/2013
-
A year into the job, KHK scientist-CEO Nobuo Hanai has set a course that would feel familiar to Western biotech CEOs, growing organically by combining the company's technology with targets from academia.
Published on 3/18/2013
-
Aurinia is reverse-merging with Isotechnika to form a publicly traded entity with a simplified ownership of voclosporin, which the newco hopes will enable it to raise the cash needed for a Phase IIb trial in lupus …
Published on 3/4/2013
-
Retiring Shire CEO Angus Russell says the industry needs a new generation of chief executives who understand markets in a way that is fundamentally different from commercially minded CEOs of the past.
Published on 3/4/2013
-
Europe Ltd. Europe's negative numbers Aggregate European sales by 10 innovator pharmas fell $10.1 billion (11%) in 2012 compared to 2011, while U.S. sales dropped $6.2 billion (5%). The U.S. falloff was driven by …
Published on 2/18/2013
-
Pharma companies are starting to shrink their footprints in Europe in the face of pressure on prices and reimbursement. But emerging markets and the U.S. won't lessen the need for new strategies to address shrinking …
Published on 2/18/2013